[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 39
1. Liu S, Wang Y, Fan X, Ma J, Ma W, Wang R, Jiang T: Anatomical Involvement of the Subventricular Zone Predicts Poor Survival Outcome in Low-Grade Astrocytomas. PLoS One; 2016;11(4):e0154539
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Lateral Ventricles / pathology
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Male. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):616-22 [23540348.001]
  • [Cites] Neuroimage. 2012 Jan 16;59(2):908-16 [22001163.001]
  • [Cites] Science. 2007 Jul 20;317(5836):381-4 [17615304.001]
  • [Cites] Acta Neuropathol. 1977 Apr 29;38(1):1-6 [193346.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4 Suppl):S207-71 [12234450.001]
  • [Cites] J Neurooncol. 2012 Aug;109(1):195-203 [22555992.001]
  • [Cites] Genome Res. 2014 Feb;24(2):329-39 [24105770.001]
  • [Cites] Cancers (Basel). 2013 Aug 14;5(3):1049-71 [24202333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846-51 [11070094.001]
  • [Cites] Biochim Biophys Acta. 2013 Feb;1830(2):2496-508 [23079585.001]
  • [Cites] J Clin Neurosci. 2013 Oct;20(10):1422-6 [23928040.001]
  • [Cites] Acta Neuropathol. 1977 Sep 26;40(1):63-71 [199034.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):424-9 [17622647.001]
  • [Cites] BMC Cancer. 2010;10:384 [20663133.001]
  • [Cites] PLoS Biol. 2007 Nov;5(11):e300 [18001150.001]
  • [Cites] J Neurooncol. 2011 Aug;104(1):261-9 [21132516.001]
  • [Cites] Neuron. 2004 Mar 4;41(5):683-6 [15003168.001]
  • [Cites] J Neurosci. 2007 Aug 1;27(31):8286-96 [17670975.001]
  • [Cites] Neurosurgery. 2010 Nov;67(5):1319-27; discussion 1327-8 [20871424.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):683-8 [11723374.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14506-11 [12381788.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Exp Mol Med. 2008 Feb 29;40(1):84-91 [18305401.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Nature. 2010 Dec 23;468(7327):1095-9 [21150899.001]
  • [Cites] Neurosurgery. 2012 Sep;71(3):729-39; discussion 739-40 [22668885.001]
  • [Cites] Nature. 2011 Jul 21;475(7356):381-5 [21776083.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Stem Cells. 2014 Jan;32(1):70-84 [23964022.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:357-65 [19022766.001]
  • [Cites] J Clin Neurosci. 2009 Feb;16(2):195-201 [19097905.001]
  • [Cites] Neuro Oncol. 2013 Jan;15(1):91-6 [23095230.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] J Neuropathol Exp Neurol. 1975 Jul;34(4):340-58 [166146.001]
  • [Cites] Stem Cells. 2014 May;32(5):1239-53 [24375787.001]
  • [Cites] Radiat Oncol. 2014;9:95 [24758192.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jan;66(1):1-9 [17204931.001]
  • (PMID = 27120204.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4847798
  •  go-up   go-down


2. Melchionda L, Fang M, Wang H, Fugnanesi V, Morbin M, Liu X, Li W, Ceccherini I, Farina L, Savoiardo M, D'Adamo P, Zhang J, Costa A, Ravaglia S, Ghezzi D, Zeviani M: Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant. Orphanet J Rare Dis; 2013 May 01;8:66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant.
  • BACKGROUND: We studied a family including two half-siblings, sharing the same mother, affected by slowly progressive, adult-onset neurological syndromes.
  • In spite of the diversity of the clinical features, characterized by a mild movement disorder with cognitive impairment in the elder patient, and severe motor-neuron disease (MND) in her half-brother, the brain Magnetic Resonance Imaging (MRI) features were compatible with adult-onset Alexander's disease (AOAD), suggesting different expression of the same, genetically determined, condition.
  • RESULTS: Exome-NGS revealed a mutation in a previously neglected GFAP isoform, GFAP-ϵ, which disrupts the GFAP-associated filamentous cytoskeletal meshwork of astrocytoma cells.
  • [MeSH-minor] Age of Onset. Aged. Brain Stem / metabolism. Brain Stem / pathology. Cells, Cultured. Exome. Female. Fibroblasts / metabolism. High-Throughput Nucleotide Sequencing. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Phenotype

  • Genetic Alliance. consumer health - Alexander Disease.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Traffic. 2012 Jun;13(6):771-9 [22372633.001]
  • [Cites] PLoS One. 2012;7(3):e33565 [22479412.001]
  • [Cites] PLoS One. 2012;7(8):e42823 [22912745.001]
  • [Cites] Mol Genet Metab. 2012 Nov;107(3):403-8 [23010432.001]
  • [Cites] EMBO Mol Med. 2013 Jan;5(1):52-63 [23184605.001]
  • [Cites] Autophagy. 2010 May;6(4):555-7 [20404488.001]
  • [Cites] J Neurosci. 2012 Apr 11;32(15):5017-23 [22496548.001]
  • [Cites] Hum Mol Genet. 1999 Dec;8(13):2533-40 [10556302.001]
  • [Cites] Nature. 2002 May 23;417(6887):455-8 [12024216.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4389-94 [12677000.001]
  • [Cites] J Child Neurol. 2003 Sep;18(9):625-32 [14572141.001]
  • [Cites] Acta Neurol Scand. 1970;46(4):493-512 [5504332.001]
  • [Cites] Neurology. 1983 Nov;33(11):1444-52 [6685237.001]
  • [Cites] Neuroepidemiology. 1989;8(3):142-50 [2725806.001]
  • [Cites] Brain Res Bull. 2005 Mar 15;65(2):155-62 [15763182.001]
  • [Cites] Hum Genet. 2006 Mar;119(1-2):137-44 [16365765.001]
  • [Cites] Nat Biotechnol. 2006 May;24(5):537-44 [16680138.001]
  • [Cites] Exp Cell Res. 2007 Jun 10;313(10):2077-87 [17498694.001]
  • [Cites] Nature. 2007 Jun 14;447(7146):859-63 [17568747.001]
  • [Cites] Mol Cell Biol. 2008 Mar;28(5):1688-701 [18180281.001]
  • [Cites] Eur J Hum Genet. 2008 Apr;16(4):462-70 [18197187.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jun;29(6):1190-6 [18388212.001]
  • [Cites] Brain. 2008 Sep;131(Pt 9):2321-31 [18684770.001]
  • [Cites] Hum Mol Genet. 2009 Mar 15;18(6):1058-64 [19124534.001]
  • [Cites] EMBO J. 2010 Jan 6;29(1):209-21 [19910924.001]
  • [Cites] EMBO J. 2010 Mar 3;29(5):969-80 [20075865.001]
  • [Cites] J Biol Chem. 2010 Oct 29;285(44):34097-105 [20720006.001]
  • [Cites] Cell Signal. 2011 May;23(5):763-71 [20940043.001]
  • [Cites] J Neurol Sci. 2011 May 15;304(1-2):1-8 [21377170.001]
  • [Cites] PLoS One. 2012;7(2):e30924 [22328923.001]
  • [Cites] Crit Rev Clin Lab Sci. 2012 Mar-Apr;49(2):33-48 [22468856.001]
  • [Cites] Hum Mutat. 2012 Jul;33(7):1141-8 [22488673.001]
  • (PMID = 23634874.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP11011; Italy / Telethon / / GPP10005
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 3.5.1.98 / HDAC6 protein, human; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC3654953
  •  go-up   go-down


3. Marsh JC, Goldman S, Ziel E, Bregman C, Diaz A, Byrne R, Fangusaro J: Involvement of the neural stem cell compartment by pediatric and adult gliomas: a retrospective review of 377 cases. J Neurooncol; 2015 Mar;122(1):105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of the neural stem cell compartment by pediatric and adult gliomas: a retrospective review of 377 cases.
  • To assess frequency of neural stem cell compartment (NSC) involvement in adult and pediatric gliomas [World Health Organization (WHO) grades 1-4], and to assess whether NSC involvement at presentation impacts on survival, recurrence rates, and/or transformation from low grade (WHO grade 1-2) to high grade disease (WHO grades 3-4).
  • Cranial MRIs for 154 pediatric and 223 adult glioma patients treated from 2000 to 2012 were reviewed.
  • Tumors were stratified by age (adult vs. pediatric), histology, tumor grade, tumor location, and involvement of midline structures.
  • Higher rates of NSC involvement were seen among adult (p = .0001); high grade (p = .0001)); grade 2 versus grade 1 (p = .0001) and other grade 1 histologies (p = .0001) versus JPA (juvenile pilocytic astrocytoma) patients); grade 2-4 tumors (p = .0001); and supratentorial tumors (p < .0001).
  • No transformation was noted among pediatric low grade tumors or adult grade 1 tumors.
  • 22/119 (18.5 %) adult grade 2 tumors transformed.
  • Adult and pediatric gliomas (all grades) frequently involve NSC at presentation, although rates are lower in pediatric JPA and all infratentorial tumors.
  • NSC involvement at presentation increases OR death and reduces TTR for pediatric gliomas (all grades) and adult low grade gliomas, and shows a strong trend toward increased ORR.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioma / pathology. Neoplasm Recurrence, Local / pathology. Neoplastic Stem Cells / pathology. Neural Stem Cells / pathology
  • [MeSH-minor] Adult. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Grading. Prognosis. Retrospective Studies. Survival Rate. Young Adult


Advertisement
4. Nie S, Gurrea M, Zhu J, Thakolwiboon S, Heth JA, Muraszko KM, Fan X, Lubman DM: Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays. J Proteome Res; 2015 Feb 6;14(2):814-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays.
  • Glioblastoma multiforme (GBM) is a highly aggressive brain tumor, with dismal survival outcomes.
  • Recently, cancer stem cells (CSCs) have been demonstrated to play a role in therapeutic resistance and are considered to be the most likely cause of cancer relapse.
  • Here, we have investigated the expression of TNC in tissue microarrays including 17 GBMs, 18 WHO grade III astrocytomas, 15 WHO grade II astrocytomas, 4 WHO grade I astrocytomas, and 7 normal brain tissue samples by immunohistochemical staining.
  • TNC expression was found to be highly associated with the grade of astrocytoma.
  • It has a high expression level in most of the grade III astrocytomas and GBMs analyzed and a very low expression in most grade II astrocytomas, whereas it is undetectable in grade I astrocytomas and normal brain tissues.
  • The results were further confirmed by flow cytometry analysis of TNC and CD133 in GBM-derived stem-like neurospheres in vitro.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2010 May 7;9(5):2565-72 [20235609.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Brain Pathol. 2010 Sep;20(5):877-89 [20331619.001]
  • [Cites] J Proteome Res. 2011 Jan 7;10(1):330-8 [21110520.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1591-6 [21220328.001]
  • [Cites] Tumour Biol. 2011 Jun;32(3):425-40 [21318290.001]
  • [Cites] Cancer Res. 2011 Sep 15;71(18):6061-72 [21788346.001]
  • [Cites] Cell Mol Life Sci. 2011 Oct;68(19):3175-99 [21818551.001]
  • [Cites] Cell Res. 2011 Oct;21(10):1470-86 [21403679.001]
  • [Cites] Acta Neuropathol. 2011 Oct;122(4):495-510 [21863242.001]
  • [Cites] Mol Cell Proteomics. 2012 Jun;11(6):M111.010744 [22203689.001]
  • [Cites] Oncogene. 2012 Jul 5;31(27):3235-43 [22056879.001]
  • [Cites] Tumour Biol. 2014 Jul;35(7):6777-82 [24722824.001]
  • [Cites] Stem Cell Res Ther. 2013;4(1):18 [23510696.001]
  • [Cites] Dev Dyn. 2000 Jun;218(2):235-59 [10842355.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Brain Res. 2003 Nov 14;990(1-2):129-40 [14568337.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] Development. 2004 Jul;131(14):3423-32 [15226258.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Liver. 1994 Jun;14(3):148-53 [7521506.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):1-19 [19468690.001]
  • [Cites] Tissue Eng Part C Methods. 2009 Sep;15(3):365-72 [19719393.001]
  • [Cites] Histol Histopathol. 2010 Mar;25(3):371-85 [20054808.001]
  • [Cites] Stem Cells. 2010 Jan;28(1):5-16 [19904829.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):733-6 [17882276.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2524-33 [17628016.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):761-8 [17955491.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Cancer Biol Ther. 2008 Mar;7(3):325-30 [18285703.001]
  • [Cites] Cells Tissues Organs. 2008;188(1-2):170-7 [18160825.001]
  • [Cites] Lab Invest. 2008 Aug;88(8):808-15 [18560366.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6043-8 [18676824.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7882-6 [18829544.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4793-807 [19064739.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):135-47 [19185848.001]
  • [Cites] Oncogene. 2009 Apr 16;28(15):1807-11 [19287454.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Pathol Oncol Res. 2005;11(4):229-35 [16388320.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):1-7 [16292494.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Neurosurg Rev. 2007 Jan;30(1):16-20; discussion 20-1 [17123059.001]
  • [Cites] Cancer Biol Ther. 2010 Mar 1;9(5):396-406 [20118657.001]
  • (PMID = 25469866.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA163737; United States / NIGMS NIH HHS / GM / R01 GM049500; United States / NCI NIH HHS / CA / R01 CA163737; United States / NCI NIH HHS / CA / R01 CA148621; United States / NIGMS NIH HHS / GM / GM R01 GM49500; United States / NCI NIH HHS / CA / R01CA148621
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tenascin
  • [Other-IDs] NLM/ NIHMS656842; NLM/ PMC4320683
  • [Keywords] NOTNLM ; GBM / cancer stem cell / marker / tenascin-C / tissue microarrays
  •  go-up   go-down


5. Cohen KJ, Gibbs IC, Fisher PG, Hayashi RJ, Macy ME, Gore L: A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol; 2013 Jun;15(6):783-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma.
  • [MeSH-major] Arsenicals / therapeutic use. Astrocytoma / therapy. Brain Stem Neoplasms / therapy. Chemoradiotherapy. Oxides / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Neoplasm Grading. Prognosis. Survival Rate. Young Adult

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):197-203 [15337556.001]
  • [Cites] Biol Chem. 2010 May;391(5):519-31 [20302512.001]
  • [Cites] Toxicol Sci. 2010 Jul;116(1):183-93 [20403967.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13432-7 [20624968.001]
  • [Cites] Can J Neurol Sci. 2010 Jul;37(4):504-11 [20724260.001]
  • [Cites] J Clin Invest. 2011 Jan;121(1):14-6 [21183780.001]
  • [Cites] J Clin Invest. 2011 Jan;121(1):148-60 [21183792.001]
  • [Cites] J BUON. 2010 Oct-Dec;15(4):758-62 [21229642.001]
  • [Cites] Biochem Biophys Res Commun. 2011 Jul 8;410(3):692-7 [21703238.001]
  • [Cites] J Mol Med (Berl). 2011 Sep;89(9):927-41 [21594580.001]
  • [Cites] J Neurooncol. 2011 Sep;104(2):449-58 [21327864.001]
  • [Cites] Cancer Treat Rev. 2012 Feb;38(1):27-35 [21764221.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6033-7 [10626785.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:11-6 [11331435.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):49-55 [12063549.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2103-8 [12727826.001]
  • [Cites] Radiat Res. 2003 Dec;160(6):662-6 [14689968.001]
  • [Cites] Biol Trace Elem Res. 1996 Summer;53(1-3):45-9 [8862736.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1389-91 [9801402.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):980-91 [15592527.001]
  • [Cites] Cancer Sci. 2005 Nov;96(11):825-33 [16271077.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):493-8 [16563655.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):266-75 [18172319.001]
  • [Cites] Blood. 2008 Jan 15;111(2):566-73 [17959855.001]
  • [Cites] Cancer Lett. 2008 Aug 18;267(1):96-105 [18439752.001]
  • [Cites] Postepy Hig Med Dosw (Online). 2008;62:463-7 [18806735.001]
  • [Cites] Zhongguo Zhong Yao Za Zhi. 2008 Sep;33(17):2150-3 [19066063.001]
  • [Cites] J Neurosurg Pediatr. 2009 Apr;3(4):259-69 [19338403.001]
  • [Cites] Autophagy. 2009 May;5(4):472-83 [19242099.001]
  • [Cites] Cancer Lett. 2010 Jun 1;292(1):64-72 [19962820.001]
  • [Cites] Environ Res. 1980 Apr;21(2):446-57 [7408817.001]
  • (PMID = 23460318.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12 CA086913; United States / NCI NIH HHS / CA / T32 CA082086
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC3661102
  • [Keywords] NOTNLM ; arsenic trioxide / astrocytoma / chemoradiotherapy / pediatrics
  •  go-up   go-down


6. Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ: A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer; 2017 Nov;64(11)
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / therapy. Brain Stem Neoplasms / therapy. Chemoradiotherapy / mortality. Glioma / therapy
  • [MeSH-minor] Adolescent. Adult. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Prognosis. Survival Rate. Young Adult

  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • [Cites] Neuro Oncol. 2015 Jan;16 Suppl 10:x1-x36 [25542864.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):33-8 [14758131.001]
  • [Cites] Neuro Oncol. 2016 Oct;18(10 ):1442-50 [27006176.001]
  • [Cites] J Neurosurg. 2006 Nov;105(5 Suppl):418-24 [17328268.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] Acta Neuropathol. 2013 May;125(5):683-98 [23429996.001]
  • [Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):8-14 [19917840.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71 [9457808.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Neuro Oncol. 2011 Apr;13(4):410-6 [21345842.001]
  • [Cites] Neuro Oncol. 2011 Mar;13(3):317-23 [21339192.001]
  • [Cites] Oncol Lett. 2014 Jul;8(1):41-46 [24959216.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1472-8 [18349398.001]
  • [Cites] Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):161-70 [16569354.001]
  • [Cites] Transl Oncol. 2011 Feb 01;4(1):47-58 [21286377.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3431-7 [12177103.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] J Neurooncol. 2014 Aug;119(1):7-15 [24792486.001]
  • [Cites] Neuro Oncol. 2009 Jun;11(3):274-80 [18981259.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1552-61 [17332301.001]
  • [Cites] J Clin Oncol. 2010 Nov 1;28(31):4747-54 [20921467.001]
  • [Cites] Acta Neuropathol. 2014 May;127(5):731-45 [24240813.001]
  • [Cites] J Transl Med. 2012 Apr 10;10 :71 [22490361.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):994-1003 [12006511.001]
  • [Cites] J Neurooncol. 2009 Apr;92 (2):165-75 [19066728.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64 [10192340.001]
  • [Cites] Clin Cancer Res. 2013 Jan 1;19(1):279-90 [23091115.001]
  • [Cites] Target Oncol. 2013 Sep;8(3):173-181 [23321777.001]
  • [Cites] Ann Oncol. 2009 Sep;20(9):1596-603 [19491283.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):301-11 [15837620.001]
  • [Cites] Clin Cancer Res. 2015 Mar 1;21(5):1078-86 [25520391.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5235-46 [16051966.001]
  • [Cites] Cytometry. 2001 Sep 1;45(1):27-36 [11598944.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):102-8 [11916501.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):279-86 [15863375.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1408-17 [19339720.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] J Clin Oncol. 2009 Oct 20;27(30):5102-8 [19770383.001]
  • (PMID = 28544128.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12 CA086913; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P30 CA046934
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0H43101T0J / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  • [Keywords] NOTNLM ; cetuximab / chemotherapy / diffuse intrinsic pontine glioma / pediatric high-grade astrocytoma / radiation
  •  go-up   go-down


7. Dorris K, Sobo M, Onar-Thomas A, Panditharatna E, Stevenson CB, Gardner SL, Dewire MD, Pierson CR, Olshefski R, Rempel SA, Goldman S, Miles L, Fouladi M, Drissi R: Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas. J Neurooncol; 2014 Mar;117(1):67-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A multi-institutional retrospective study was conducted involving 50 flash-frozen HGG (35 non-brainstem; 15 DIPG) tumors from 45 children (30 non-brainstem; 15 DIPG).
  • High TERC and hTERT expression was detected in 13/28 non-brainstem HGG samples as compared to non-neoplastic controls.
  • Evidence of ALT was noted in 3/11 DIPG and 10/19 non-brainstem HGG specimens.
  • ALT and telomerase use were identified in 4/19 non-brainstem HGG and 2/11 DIPG specimens.
  • In multivariable analyses, increased TERC and hTERT levels were associated with worse OS in patients with non-brainstem HGG, after controlling for tumor grade or resection extent.
  • In children with non-brainstem HGG, increased TERC and hTERT expression levels are associated with a worse OS, making telomerase a promising potential therapeutic target in pediatric HGG.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Stem Neoplasms / metabolism. Glioma / metabolism. Telomere / metabolism
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / metabolism. Astrocytoma / pathology. Astrocytoma / surgery. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplasm Grading. Prognosis. RNA / metabolism. RNA, Messenger / metabolism. Retrospective Studies. Telomerase / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Cancer Lett. 2013 Oct 28;340(1):82-7 [23850566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9082-6 [7568077.001]
  • [Cites] Lancet. 1995 Nov 11;346(8985):1267-8 [7475720.001]
  • [Cites] Cancer Res. 1996 Feb 1;56(3):645-50 [8564985.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):200-4 [8563761.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1236-41 [7544491.001]
  • [Cites] J Neurooncol. 1999 Jun;43(2):137-42 [10533725.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2038-44 [10570429.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2582-92 [10893290.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):647-50 [11107138.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):651-5 [11107139.001]
  • [Cites] Gene. 2001 May 16;269(1-2):1-12 [11376932.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7594-602 [11606399.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):598-610 [11850785.001]
  • [Cites] Lancet. 2003 Mar 8;361(9360):836-8 [12642053.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3931-9 [12873987.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):1-8 [14769133.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):972-9 [15280920.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3790-7 [15365076.001]
  • [Cites] Nature. 1991 Apr 18;350(6319):569-73 [1708110.001]
  • [Cites] EMBO J. 1992 May;11(5):1921-9 [1582420.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):921-6 [9175740.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(5):787-91 [9282118.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):498-502 [9398860.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1558-61 [9537264.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1120-4; discussion 1124-5 [9588558.001]
  • [Cites] Hum Pathol. 1998 Jun;29(6):599-603 [9635680.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):551-7 [9973199.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):741-9 [10091748.001]
  • [Cites] Mol Cell Biol. 1999 Jun;19(6):3989-97 [10330139.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4301-7 [10485476.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9138-45 [16172460.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1522-8 [16575002.001]
  • [Cites] Int J Oncol. 2006 Jun;28(6):1555-60 [16685456.001]
  • [Cites] Cancer Invest. 2007 Apr-May;25(3):197-208 [17530490.001]
  • [Cites] Oncol Rep. 2007 Dec;18(6):1571-6 [17982646.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] Br J Radiol. 2008 Sep;81(969):711-20 [18541630.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):914-23 [19188162.001]
  • [Cites] Cell. 2010 Mar 5;140(5):678-91 [20211137.001]
  • [Cites] Genes Dev. 2010 Jun 15;24(12):1253-65 [20504901.001]
  • [Cites] J Neuropathol Exp Neurol. 2010 Jul;69(7):729-36 [20535033.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14075-80 [20651253.001]
  • [Cites] Nat Protoc. 2010 Sep;5(9):1596-607 [21085125.001]
  • [Cites] Stem Cells. 2011 Mar;29(3):440-51 [21425407.001]
  • [Cites] Am J Pathol. 2011 Oct;179(4):1608-15 [21888887.001]
  • [Cites] PLoS One. 2011;6(10):e26737 [22046342.001]
  • [Cites] Nature. 2012 Feb 9;482(7384):226-31 [22286061.001]
  • [Cites] Nat Genet. 2012 Mar;44(3):251-3 [22286216.001]
  • [Cites] Acta Neuropathol. 2012 Sep;124(3):439-47 [22661320.001]
  • [ErratumIn] J Neurooncol. 2014 Aug;119(1):223-4
  • (PMID = 24477622.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016087; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCATS NIH HHS / TR / UL1 TR001425; United States / NIEHS NIH HHS / ES / T32 ES010957; United States / NCRR NIH HHS / RR / UL1 RR026314; United States / NCRR NIH HHS / RR / UL1RR026314
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / telomerase RNA; 63231-63-0 / RNA; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ NIHMS646350; NLM/ PMC4261223
  •  go-up   go-down


8. Smith SJ, Tilly H, Ward JH, Macarthur DC, Lowe J, Coyle B, Grundy RG: CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol; 2012 Jul;124(1):99-110
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paediatric high grade glioma (pHGG) (World Health Organisation astrocytoma grades III and IV) remains poor prognosis tumours, with a median survival of only 15 months following diagnosis.
  • Current investigation of anti-angiogenic strategies has focused on adult glioblastoma multiforme (GBM) with phase III trials targeting vascular endothelial growth factor continuing.
  • [MeSH-major] Antigens, CD / metabolism. Brain Neoplasms / diagnosis. Glioma / diagnosis. Neovascularization, Pathologic / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Adolescent. Antigens, CD31 / metabolism. Child. Child, Preschool. Cohort Studies. Female. Gene Expression / physiology. Humans. Infant. Infant, Newborn. Kaplan-Meier Estimate. Ki-67 Antigen / metabolism. Male. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2010 Apr 15;29(15):2181-91 [20101215.001]
  • [Cites] J Clin Oncol. 2010 Jun 10;28(17):2817-23 [20458050.001]
  • [Cites] J Clin Oncol. 2010 Jun 20;28(18):3061-8 [20479398.001]
  • [Cites] Mutagenesis. 2010 Sep;25(5):447-54 [20501547.001]
  • [Cites] Neurosurgery. 2010 Oct;67(4):1124-32 [20881577.001]
  • [Cites] Breast Cancer Res Treat. 2010 Nov;124(1):27-38 [20035377.001]
  • [Cites] Anticancer Res. 2010 Sep;30(9):3301-8 [20944101.001]
  • [Cites] Nature. 2010 Dec 9;468(7325):829-33 [21102433.001]
  • [Cites] Nature. 2010 Dec 9;468(7325):824-8 [21102434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4274-80 [21262804.001]
  • [Cites] Cancer Res. 2011 Sep 15;71(18):6061-72 [21788346.001]
  • [Cites] Neuro Oncol. 2011 Nov;13(11):1171-7 [21849329.001]
  • [Cites] Childs Nerv Syst. 2001 Oct;17(10):577-83 [11685518.001]
  • [Cites] J Hum Genet. 2002;47(3):136-9 [11954550.001]
  • [Cites] Eur J Hum Genet. 2003 Apr;11(4):315-24 [12700605.001]
  • [Cites] FASEB J. 2003 Jun;17(9):984-92 [12773481.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2677-85 [12746487.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6557-63 [14528280.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3716-20 [15116102.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):347-56 [4347034.001]
  • [Cites] Surg Neurol. 1985 Jan;23(1):64-8 [3964979.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Annu Rev Cell Dev Biol. 1995;11:73-91 [8689573.001]
  • [Cites] Exp Hematol. 1999 Aug;27(8):1282-94 [10428505.001]
  • [Cites] Croat Med J. 2005 Jun;46(3):417-22 [15861521.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):179-83 [15925999.001]
  • [Cites] Neuropathology. 2005 Sep;25(3):201-6 [16193836.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Oct;32(5):532-8 [16972887.001]
  • [Cites] Lung Cancer. 2007 Jan;55(1):53-60 [17067717.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):279-84 [17530177.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Stem Cells. 2007 Nov;25(11):2739-49 [17656645.001]
  • [Cites] Neuropathology. 2008 Feb;28(1):17-23 [18181830.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):370-7 [18371181.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7882-6 [18829544.001]
  • [Cites] J Neurooncol. 2008 Nov;90(2):157-70 [18612800.001]
  • [Cites] Cancer Sci. 2008 Oct;99(10):1916-23 [19016750.001]
  • [Cites] Mol Cancer Res. 2009 Apr;7(4):489-97 [19372578.001]
  • [Cites] Br J Cancer. 2009 May 19;100(10):1617-26 [19352388.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14478-83 [19667180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17389-94 [19805025.001]
  • [Cites] Int J Mol Med. 2009 Dec;24(6):789-94 [19885619.001]
  • [Cites] Cell Cycle. 2009 Nov 15;8(22):3695-701 [19855166.001]
  • [Cites] Cell Stem Cell. 2010 Feb 5;6(2):141-52 [20144787.001]
  • [Cites] Cardiovasc Res. 2010 Apr 1;86(1):12-9 [19812043.001]
  • [Cites] Nat Med. 2010 Apr;16(4):420-8 [20364125.001]
  • (PMID = 22311740.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / ENG protein, human; 0 / Ki-67 Antigen; 0 / Receptors, Cell Surface; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC3377898
  •  go-up   go-down


9. Lewis KM, Petritsch C: ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT. Transl Neurosci; 2013 Dec;4(4):484-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the discovery of continuous neuro-gliogenesis in the normal adult brain and the identification of brain tumor stem cells within glioma have led to the hypothesis that these brain tumors originate from multipotent neural stem or progenitor cells, which primarily divide asymmetrically during the postnatal period.
  • In contrast, there is some evidence that asymmetric cell division maintenance in tumor stem-like cells within astrocytoma may lead to acquisition of treatment resistance.
  • Therefore cell division mode in normal brain stem and progenitor cells may play a role in setting tumorigenic potential and the type of tumor formed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25530875.001).
  • [ISSN] 2081-3856
  • [Journal-full-title] Translational neuroscience
  • [ISO-abbreviation] Transl Neurosci
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA164746; United States / NINDS NIH HHS / NS / R01 NS080619
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Astrocytoma / Asymmetric cell division / Brain tumor / Cancer stem cell / Cell of origin / Chemotherapy / Oligodendroglioma / Progenitor cell / Stem cell / Symmetrical cell division
  •  go-up   go-down


10. Ishii A, Kimura T, Sadahiro H, Kawano H, Takubo K, Suzuki M, Ikeda E: Histological Characterization of the Tumorigenic "Peri-Necrotic Niche" Harboring Quiescent Stem-Like Tumor Cells in Glioblastoma. PLoS One; 2016;11(1):e0147366
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological Characterization of the Tumorigenic "Peri-Necrotic Niche" Harboring Quiescent Stem-Like Tumor Cells in Glioblastoma.
  • BACKGROUND: Characterization of the niches for stem-like tumor cells is important to understand and control the behavior of glioblastomas.
  • Cell-cycle quiescence might be a common mechanism underlying the long-term maintenance of stem-cell function in normal and neoplastic stem cells, and our previous study demonstrated that quiescence induced by hypoxia-inducible factor (HIF)-1α is associated with a high long-term repopulation capacity of hematopoietic stem cells.
  • Based on this, we examined human astrocytoma tissues for HIF-1α-regulated quiescent stem-like tumor cells as a candidate for long-term tumorigenic cells and characterized their niche histologically.
  • METHODS: Multi-color immunohistochemistry was used to visualize HIF-1α-expressing (HIF-1α+) quiescent stem-like tumor cells and their niche in astrocytoma (WHO grade II-IV) tissues.
  • RESULTS: A small subpopulation of HIF-1α+ quiescent stem-like tumor cells was found in glioblastomas but not in lower-grade astrocytomas.
  • We successfully modeled this niche containing cells of HIF-1α+ quiescent stem-like phenotype by incubating glioblastoma cell spheroids under an appropriately hypoxic condition, and the emergence of HIF-1α+ quiescent stem-like cells was shown to be associated with an enhanced sphere-forming activity.
  • CONCLUSIONS: These data suggest that the "peri-necrotic niche" harboring HIF-1α+ quiescent stem-like cells confers a higher tumorigenic potential on glioblastoma cells and therefore may be a therapeutic target to control the behavior of glioblastomas.
  • [MeSH-major] Glioblastoma / pathology. Neoplastic Stem Cells / cytology. Stem Cell Niche
  • [MeSH-minor] Adult. Aged. Astrocytoma / pathology. Biomarkers, Tumor / metabolism. Female. Fluorescent Antibody Technique. Homeodomain Proteins / metabolism. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Male. Middle Aged. SOXB1 Transcription Factors / metabolism. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Neurosurg Focus. 2014 Dec;37(6):E6 [25434391.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5262-7 [11431368.001]
  • [Cites] J Neurooncol. 2008 Nov;90(2):157-70 [18612800.001]
  • [Cites] Cell Stem Cell. 2009 Mar 6;4(3):226-35 [19265662.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1795(2):162-72 [19344680.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):440-52 [19427293.001]
  • [Cites] Stem Cells. 2009 Jan;27(1):40-8 [18948646.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):501-13 [19477429.001]
  • [Cites] Clin Exp Metastasis. 2009;26(7):611-23 [19421880.001]
  • [Cites] Oncogene. 2009 Nov 12;28(45):3949-59 [19718046.001]
  • [Cites] Cell. 2010 Jan 8;140(1):62-73 [20074520.001]
  • [Cites] Cell Stem Cell. 2010 Feb 5;6(2):141-52 [20144787.001]
  • [Cites] Cancer Res. 2010 Mar 1;70(5):2010-9 [20179204.001]
  • [Cites] Blood. 2001 Feb 1;97(3):720-8 [11157490.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):65-73 [8699228.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Pathol Int. 2005 Oct;55(10):603-10 [16185289.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Brain. 2010 Apr;133(Pt 4):983-95 [20375133.001]
  • [Cites] Cell. 2010 May 14;141(4):583-94 [20478252.001]
  • [Cites] Cell Stem Cell. 2010 Aug 6;7(2):150-61 [20682444.001]
  • [Cites] EMBO J. 2010 Aug 4;29(15):2659-74 [20581802.001]
  • [Cites] Cell Stem Cell. 2010 Sep 3;7(3):391-402 [20804974.001]
  • [Cites] Stem Cells. 2010 Sep;28(9):1571-80 [20641035.001]
  • [Cites] Cancer Cell. 2010 Dec 14;18(6):655-68 [21156287.001]
  • [Cites] J Neurooncol. 2011 Mar;102(1):43-50 [20596750.001]
  • [Cites] Brain. 2011 May;134(Pt 5):1331-43 [21515906.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2010;75:237-44 [21047904.001]
  • [Cites] Clin Cancer Res. 2011 Aug 1;17(15):4936-41 [21593194.001]
  • [Cites] Cell Death Differ. 2012 Feb;19(2):284-94 [21818118.001]
  • [Cites] Cell. 2012 Mar 30;149(1):36-47 [22464322.001]
  • [Cites] Nature. 2012 Aug 23;488(7412):522-6 [22854781.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):111-7 [22665270.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):119-23 [22678420.001]
  • [Cites] Mol Cell. 2012 Dec 14;48(5):681-91 [23103253.001]
  • [Cites] Biochim Biophys Acta. 2013 Jan;1829(1):55-62 [22982363.001]
  • [Cites] Biochim Biophys Acta. 2013 Feb;1830(2):2496-508 [23079585.001]
  • [Cites] Nat Rev Mol Cell Biol. 2013 Jun;14(6):329-40 [23698583.001]
  • [Cites] Cell Stem Cell. 2014 Mar 6;14(3):357-69 [24607407.001]
  • [Cites] J Pathol. 2014 Sep;234(1):11-22 [24604164.001]
  • [Cites] Neuro Oncol. 2014 Sep;16(9):1167-75 [24642524.001]
  • [Cites] Cell Mol Life Sci. 2014 Sep;71(18):3569-82 [24858415.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):335-47 [17418410.001]
  • (PMID = 26799577.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Homeodomain Proteins; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / NANOG protein, human; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors
  • [Other-IDs] NLM/ PMC4723051
  •  go-up   go-down






Advertisement